Logo image of SCPX

SCORPIUS HOLDINGS INC (SCPX) Stock Price, Forecast & Analysis

USA - NYSE Arca - NYSEARCA:SCPX - US42237K5083 - Common Stock

0.068 USD
-0.06 (-48.48%)
Last: 4/21/2025, 8:04:00 PM

SCPX Key Statistics, Chart & Performance

Key Statistics
Market Cap331.16K
Revenue(TTM)9.74M
Net Income(TTM)-36.85M
Shares4.87M
Float230.00K
52 Week High7.22
52 Week Low0.06
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.38
PEN/A
Fwd PEN/A
Earnings (Next)05-26
IPO2013-07-24
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
SCPX short term performance overview.The bars show the price performance of SCPX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

SCPX long term performance overview.The bars show the price performance of SCPX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of SCPX is 0.068 USD. In the past month the price decreased by -59.04%. In the past year, price decreased by -78.97%.

SCORPIUS HOLDINGS INC / SCPX Daily stock chart

SCPX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SCPX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SCPX. SCPX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCPX Financial Highlights

Over the last trailing twelve months SCPX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 20.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -72.96%
ROE -128.83%
Debt/Equity 0.31
Chartmill High Growth Momentum
EPS Q2Q%68%
Sales Q2Q%356.36%
EPS 1Y (TTM)20.42%
Revenue 1Y (TTM)947.53%

SCPX Forecast & Estimates

7 analysts have analysed SCPX and the average price target is 5.1 USD. This implies a price increase of 7400% is expected in the next year compared to the current price of 0.068.

For the next year, analysts expect an EPS growth of 97.7% and a revenue growth 63.27% for SCPX


Analysts
Analysts82.86
Price Target5.1 (7400%)
EPS Next Y97.7%
Revenue Next Year63.27%

SCPX Ownership

Ownership
Inst Owners0.19%
Ins Owners0.71%
Short Float %0.13%
Short Ratio0

About SCPX

Company Profile

SCPX logo image Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.

Company Info

SCORPIUS HOLDINGS INC

1305 E. Houston Street, Building 2

San Antonio TEXAS US

Employees: 83

SCPX Company Website

SCPX Investor Relations

Phone: 19192407133

SCORPIUS HOLDINGS INC / SCPX FAQ

What does SCPX do?

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.


Can you provide the latest stock price for SCORPIUS HOLDINGS INC?

The current stock price of SCPX is 0.068 USD. The price decreased by -48.48% in the last trading session.


Does SCPX stock pay dividends?

SCPX does not pay a dividend.


How is the ChartMill rating for SCORPIUS HOLDINGS INC?

SCPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is SCPX stock listed?

SCPX stock is listed on the NYSE Arca exchange.


Can you provide the PE ratio for SCPX stock?

SCORPIUS HOLDINGS INC (SCPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).


Is SCORPIUS HOLDINGS INC (SCPX) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCPX.